WHAT IS CLAIMED IS:

1. Use of a composition comprising of allogeneic cells wherein at least a portion of the cells are activated T-cells in the manufacture of a medicament for increasing plasma levels of endogenous IL-12 in a patient;

wherein the composition is to be administered to the patient; wherein the levels of endogenous IL-12 is to be monitored and wherein the composition is to be re-administered until endogenous IL-12 in the plasma of the patient is at least about 5000pg/ml.

2. The use of claim 1 wherein the level of IL-12 is not toxic to the patient.

3. The use of claim 1 wherein the activated T-cells are CD4+ Th1 cells.

4. The use of claim 1 wherein the level of IL-12 in the plasma of the patient is at least about 8,000 pg/ml.

5. The use of claim 3 wherein the Th1 cells are activated by cross-linking CD3 and CD28.

6. The use of claim 1 wherein administration of the composition increases the level of IFN-gamma in the patient and/or the Th1 response.

7. The use of claim 1 wherein the level of IL-12 in the plasma of the patient is at least about 20,000 pg/ml.

8. The use of claim 1, wherein the patient has cancer or an infectious disease.

9. Use of a composition comprising allogeneic cells wherein at least a portion are activated T-cells, in the manufacture of a medicament for treating a disease in a patient, wherein the T-cells are activated by cross-linking one or more agents bound to the cell surface moieties on the T-cells; wherein the composition is to be administered to the patient; wherein the levels of endogenous IL-12 in the patient's plasma is to be monitored; and wherein the composition is to be re-administered until endogenous IL-12 in the plasma of the patient is at least about 5000 pg/ml.

10. The use of claim 9 wherein the disease is cancer or is a result of a pathogenic infection.

11. The use of claim 9 wherein the readministration is to be repeated until the concentration of the endogenous IL-12 is at least 8000 pg/ml.

12. Use of a therapeutic composition comprising activated allogeneic T cells in the manufacture of a medicament for increasing the endogenous levels of IL-12 wherein the administration of the medicament leads to endogenous IL-12 of at least 5000pg/ml in the plasma of a patient without toxicity to the patient.

13. The use of claim 13 wherein the patient has cancer or an infectious disease.

14. The use of claim 13 wherein the T-cells are CD4+ cells.

15. The use of claim 13 wherein the T-cells are activated by cross-linking one or more agents that are bound to the cell surface moieties of the T-cells.

16. The composition of claim 12 wherein the one or more agents are monoclonal antibodies such as anti-CD3 and anti-CD28 monoclonal antibodies.